Julie B. Hjerpsted
Malov, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans.
Journal: Molecular metabolism
Published: February 10, 2025
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: January 14, 2025
Prevalence of Baseline Cardiac Arrhythmias in Participants with Overweight or Obesity in Phase 1 Clinical Trials: Analysis of 24-Hour Holter Electrocardiogram Recordings.
Journal: Journal of clinical pharmacology
Published: October 06, 2022
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
Journal: Diabetes, obesity & metabolism
Published: July 10, 2017
Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.
Journal: Diabetes, obesity & metabolism
Published: April 26, 2017
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Journal: Diabetes, obesity & metabolism
Published: December 06, 2016
Cheese and Cardiovascular Disease Risk: A Review of the Evidence and Discussion of Possible Mechanisms.
Journal: Critical reviews in food science and nutrition
Published: January 21, 2015
Palm olein increases plasma cholesterol moderately compared with olive oil in healthy individuals.
Journal: The American journal of clinical nutrition
Published: November 11, 2011
Cheese intake in large amounts lowers LDL-cholesterol concentrations compared with butter intake of equal fat content.
Journal: The American journal of clinical nutrition
Published: October 28, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026